Loading clinical trials...

Treating the Partners of Drug Using Pregnant Women: Stage II | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

Treating the Partners of Drug Using Pregnant Women: Stage II

NCT00496990•Johns Hopkins University

Summary

This is a two group randomized design that will compare a novel therapy package (i.e., Research supported treatment intervention, Contingency-based voucher incentives for the male partner's drug abstinence, Specialized MI couples counseling) to standard care for helping drug using partners of drug dependent pregnant women obtain and maintain drug abstinence. Participants will be followed for 22 weeks and have scheduled twice weekly urine sample collection and all participants will have follow-up interviews post-study entry.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•are 18 years of age or older on admission;
•Pregnant as determined by sonogram results
•have a current sexual partner who they have seen recently at least 3 times a week
•male partner has regular alcohol or illicit drug use (at least 4 of 7 days typical use) and is not incarcerated.

Exclusion Criteria

•woman or partner report current suicidal ideation
•woman or partner meet diagnostic criteria for a current DSM-IV Axis I thought disorder (i.e. schizophrenia)
•woman or partner demonstrate significant cognitive impairment that precludes them from completing the initial assessment battery
•woman has evidence of physical violence or abuse

Locations (1)

Center for Addiction and Pregnancy Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Key Dates

Start Date

October 1, 2005

Primary Completion Date

June 1, 2009

Completion Date

June 1, 2010

Last Updated

March 5, 2013

Enrollment

158

ACTUAL participants

Conditions

Drug Addiction

Interventions

Enhanced care

BEHAVIORAL

control

BEHAVIORAL

The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals

NCT07033728

Drug Addiction

View study

COMPLETEDNA

The Cognitive Neural Mechanisms and Neuroregulatory Interventions of Realistic Creative Problem-solving Under the Effects of Drug Addiction

NCT06917534

Drug Addiction

View study

UNKNOWN

Construction of Early Warning Model for the New Psychoactive Substances Using in Adolescents

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treating the Partners of Drug Using Pregnant Women: Stage II

Inclusion Criteria

Exclusion Criteria

The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals

The Cognitive Neural Mechanisms and Neuroregulatory Interventions of Realistic Creative Problem-solving Under the Effects of Drug Addiction

Construction of Early Warning Model for the New Psychoactive Substances Using in Adolescents

Westlake Personalized Nutrition and Health Cohort for Drug Addicts

Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray

RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing